Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Riboflavin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.72 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 7/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.89 |
| ▸ | USP2 | O75604 | 4/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.89 |
| ▸ | HAT1 | O14929 | 4/20 | 0.89 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.89 |
| ▸ | HTT | P42858 | 4/20 | 0.89 |
| ▸ | RECQL | P46063 | 3/20 | 0.89 |
| ▸ | CASP7 | P55210 | 3/20 | 0.89 |
| ▸ | MAPT | P10636 | 3/20 | 0.89 |
| ▸ | CASP1 | P29466 | 2/20 | 0.89 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.89 |
| ▸ | TST | Q16762 | 2/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.89 |
| ▸ | LMNA | P02545 | 1/20 | 0.89 |
| ▸ | HBB | P68871 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riboflavin SCHEMBL21805317 | 1.00 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL296802 | 1.00 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL367681 | 0.99 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL5477646 | 0.98 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL2241206 | 0.98 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL1085509 | 0.98 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL535031 | 0.97 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL27866166 | 0.97 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL50154 | 0.97 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL367680 | 0.96 | MEN1 (0.85) | MEN1KMT2AUSP2KDM4EHAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056386-A | Moisture absorption resistant slow release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122030612-A | Shear-resistant slow-release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-118738489-B | Preparation method of molecular-driven high-performance sulfur-based flow battery | 长沙理工大学 | 2025-01-14 | — | — | CN | claimed |
| CN-118453553-A | Application of gingerol vanillylacetone in preparation of medicine for treating colorectal cancer | 华中科技大学同济医学院附属协和医院 | 2024-08-09 | — | — | CN | claimed |
| WO-2024148248-A1 | DERMAL REJUVENATION COMPOSITION COMPRISING PLACENTA DERIVED BIOMATERIAL AND USES THEREOF | CELULARITY INC. (US) | 2024-07-11 | — | — | WO | claimed |
| CN-110974721-B | Face-repairing powder ball and preparation method thereof | 娇时日化（杭州）股份有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-112245403-B | Phosphodiesterase-4 inhibitor and oral solid composition thereof | 杭州朱养心药业有限公司 | 2022-04-22 | — | — | CN | claimed |
| US-20210315799-A1 | Composition for Promoting Differentiation or Proliferation of Human Adipose-Derived Stem Cell | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2021-10-14 | — | — | US | claimed |
| CN-112638357-A | Composition for promoting differentiation or proliferation of human adipose-derived stem cells | 株式会社LG生活健康 | 2021-04-09 | — | — | CN | claimed |
| CN-112305107-A | Apremilast composition of phosphodiesterase-4 inhibitor and quality detection method | 杭州朱养心药业有限公司 | 2021-02-02 | — | — | CN | claimed |
| CN-102206233-A | Industrial preparation method for riboflavine sodium phosphate | HUBEI GUANGJI PHARMACEUTICAL CO LTD | 2011-10-05 | — | — | CN | claimed |
| CN-101518516-B | Sodium riboflavin phosphate lyophilized powder for injection and preparation method thereof | JINXIU HUANG | 2010-09-29 | — | — | CN | claimed |
| CN-101518516-A | Sodium riboflavin phosphate lyophilized powder for injection and preparation method thereof | JINXIU HUANG | 2009-09-02 | — | — | CN | claimed |
| EP-1824349-A1 | PRODUCTION PROCESS FOR MAKING DIETETIC PRODUCT - ORAL TABLETS CONTAINING BEEBREAD AND VITAMIN C | Mogorovic, Milos (YU) | 2007-08-29 | — | — | EP | claimed |
| EP-1819239-A1 | DRY CONCENTRATE FOR MAKING DIETETIC SOFT DRINK WITH BEEBREAD AND ITS PRODUCTION PROCESS | Mogorovic, Milos (YU) | 2007-08-22 | — | — | EP | claimed |
| US-20070081913-A1 | Iron base sintered alloy having highly densified and hardened surface, and producing method thereof | MITSUBISHI MATERIALS CORPORATION (JP) | 2007-04-12 | — | — | US | claimed |
| WO-2006066283-A1 | PRODUCTION PROCESS FOR MAKING DIETETIC PRODUCT - ORAL TABLETS CONTAINING BEEBREAD AND VITAMIN C | MOGOROVIC MILOS (YU) | 2006-06-22 | — | — | WO | claimed |
| WO-2006066284-A1 | DRY CONCENTRATE FOR MAKING DIETETIC SOFT DRINK WITH BEEBREAD AND ITS PRODUCTION PROCESS | MOGOROVIC MILOS (YU) | 2006-06-22 | — | — | WO | claimed |
| EP-1640469-A1 | IRON BASE SINTERED ALLOY EXHIBITING HIGH SURFACE DENSIFICATION AND HIGH SURFACE HARDNESS, AND METHOD FOR PRODUCTION THEREOF | MITSUBISHI MATERIALS CORPORATION (JP) | 2006-03-29 | — | — | EP | claimed |
| US-5044091-A | Frozen first and second liquid freeze dried together | SANKYO COMPANY, LIMITED (JP) | 1991-09-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315799-A1 | Composition for Promoting Differentiation or Proliferation of Human Adipose-Derived Stem Cell | LRBA, FABP4, ALOX15 | ADRB2 1799/4885ADRA1A 1787/4885MEN1 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.